Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 3/20 | 0.45 |
| ▸ | IKBKB | O14920 | 3/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705839 | 0.86 | ROCK1 (0.49) | ROCK1IKBKBPRKCZROCK2HRH3 | |
| SCHEMBL1705333 | 0.85 | IKBKB (0.43) | ROCK1IKBKBNAMPTCYP2C9ROCK2 | |
| SCHEMBL1705560 | 0.85 | IKBKB (0.43) | ROCK1IKBKBNAMPTCYP2C9ROCK2 | |
| SCHEMBL1705073 | 0.84 | ROCK2 (0.49) | ROCK1IKBKBPRKCZROCK2HRH3 | |
| SCHEMBL1705684 | 0.84 | IKBKB (0.51) | ROCK1IKBKBPRKCZROCK2HRH3 | |
| SCHEMBL1705995 | 0.84 | ROCK1 (0.47) | ROCK1IKBKBPRKCZROCK2HRH3 | |
| SCHEMBL1705744 | 0.83 | NAMPT (0.48) | ROCK1IKBKBPRKCZNAMPTROCK2 | |
| SCHEMBL1705071 | 0.82 | ROCK1 (0.53) | ROCK1IKBKBPRKCZROCK2HRH3 | |
| SCHEMBL1705070 | 0.82 | ROCK1 (0.53) | ROCK1IKBKBPRKCZROCK2HRH3 | |
| SCHEMBL1705674 | 0.82 | ROCK1 (0.53) | ROCK1IKBKBPRKCZROCK2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710228-B2 | Cycloalkylamine substituted isoquinoline derivatives | SANOFI (FR) | 2014-04-29 | — | — | US | claimed |
| EP-2125746-B1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES | SANOFI SA (FR) | 2012-04-18 | — | — | EP | claimed |
| US-8710228-B2 | Cycloalkylamine substituted isoquinoline derivatives | SANOFI (FR) | 2014-04-29 | — | — | US | disclosed |
| US-8710228-B2 | Cycloalkylamine substituted isoquinoline derivatives | SANOFI (FR) | 2014-04-29 | — | — | US | disclosed |
| US-8710228-B2 | Cycloalkylamine substituted isoquinoline derivatives | SANOFI (FR) | 2014-04-29 | — | — | US | disclosed |
| EP-2125746-B1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES | SANOFI SA (FR) | 2012-04-18 | — | — | EP | disclosed |
| US-20100081671-A1 | Cycloalkylamine substituted isoquinoline derivatives | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | disclosed |
| US-20100081671-A1 | Cycloalkylamine substituted isoquinoline derivatives | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | disclosed |
| US-20100081671-A1 | Cycloalkylamine substituted isoquinoline derivatives | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081671-A1 | Cycloalkylamine substituted isoquinoline derivatives | MYLK2, MYLK, MYLK3 | ROCK1 8/4885IKBKB 1991/4885PRKCZ 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.